TransCelerate Launches Two New Global Initiatives
TransCelerate BioPharma has established two new global initiatives in the clinical trials area. Both initiatives - Placebo / Standard of Care Data Sharing and Electronic Labels for Clinical Trials (e-Labels), are made possible through the collaboration of participating Member Companies.
The Placebo / Standard of Care Data Sharing Initiative is to create a framework for data sharing that allows for the leverage of data from previous studies respecting boundaries of informed consent. It offers the potential for more rapid understanding of safety signals to better manage patient safety during clinical trials, as well as identify statistical techniques that may deliver more accurate study design and statistical power calculations. The platform will be provided to Member Company biostatisticians to hopefully lead to improved protocol development, reduction in protocol amendments and a better understanding of disease models to identify the right targets. The goal is to maximize the value from the data generated from a patient participating in a clinical trial, as well as the R&D investment.
The e-Labels Initiative will support TransCelerate Member Companies in establishing an innovative information channel: Electronic Labels (e-Labels). This initiative will work to enhance label utility for patients, provide more consistent labeling approaches for sites and offers the potential to reduce clinical labeling timelines and provides cost efficiencies for sponsors. The Initiative, in collaboration with Regulatory Agencies, will develop guidance to facilitate implementation of e-Labeling.
Newsletter
Stay current in clinical research with Applied Clinical Trials, providing expert insights, regulatory updates, and practical strategies for successful clinical trial design and execution.
Related Articles
- How the NIMBLE Study Supported Adherence With Quarterly Dosing of Cemdisiran
September 18th 2025
- Everything to Know About FDA’s Push Towards Radical Transparency in 2025
September 17th 2025
- IQVIA and Veeva Join Forces to Improve Efficiency and Patient Outcomes
September 17th 2025
- Managing Background Therapies in the NIMBLE Phase III Trial
September 17th 2025